Arcus Biosciences Completes $287.5 Million Public Offering of Common Stock
Arcus Biosciences (RCUS) secures $287.5 million in a public offering of 16,428,572 shares, netting $269.7 million to support its clinical development programs.
ALFA USA News
Straight from the SEC filing
Every SEC filing by Arcus Biosciences, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (23 Oct 2026). Not a valuation or a recommendation.
Down 23.8% over the last month ($22.14 on 19 Oct → $16.86 on 16 Nov). Daily closing prices. Source: Yahoo Finance.
| 19 Oct | $22.14 |
|---|---|
| 20 Oct | $23.75 |
| 21 Oct | $19.10 |
| 22 Oct | $19.36 |
| 23 Oct | $18.54 |
| 26 Oct | $17.76 |
| 27 Oct | $18.14 |
| 28 Oct | $18.39 |
| 29 Oct | $18.61 |
| 30 Oct | $18.19 |
| 2 Nov | $17.85 |
| 3 Nov | $18.91 |
| 4 Nov | $19.31 |
| 5 Nov | $17.69 |
| 6 Nov | $18.28 |
| 9 Nov | $18.95 |
| 10 Nov | $18.67 |
| 11 Nov | $18.80 |
| 12 Nov | $17.77 |
| 13 Nov | $17.43 |
| 16 Nov | $16.86 |
Arcus Biosciences (RCUS) secures $287.5 million in a public offering of 16,428,572 shares, netting $269.7 million to support its clinical development programs.
Arcus Biosciences (RCUS) reveals clinical data for casdatifan in ccRCC, showing a 50% confirmed objective response rate in first-line treatment combinations.
Track Arcus Biosciences, Inc. live
Get the next Arcus Biosciences, Inc. SEC filing seconds after it lands.